Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide yellow; propylene glycol; copovidone; colloidal anhydrous silica; arginine; maize starch; purified talc; magnesium stearate; titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin.,trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea.,trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor.,trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nevirapine -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: mannitol; pregelatinised maize starch; maize starch; copovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 6000; iron oxide red - trajenta is indicated in adult patients with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise,,- as monotherapy when metformin and sulfonylureas are not tolerated, or are contraindicated, or,- as add on to metformin, sulfonylureas or metformin plus sulfonylureas, or to insulin (with or without metformin) or,- as add on to metformin plus sglt2 inhibitors.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 21 microgram/actuation - inhalation, pressurised - excipient ingredients: ethanol absolute; citric acid; purified water; norflurane - atrovent metered aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with asthma and chronic obstructive pulmonary disease (copd).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide,telmisartan -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide,telmisartan -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - meloxicam, quantity: 15 mg - tablet, uncoated - excipient ingredients: povidone; colloidal anhydrous silica; sodium citrate dihydrate; microcrystalline cellulose; magnesium stearate; crospovidone; lactose monohydrate - mobic tablets and capsules are indicated for the symptomatic treatment of osteoarthritis and rheumatoid arthritis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - meloxicam, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: crospovidone; sodium citrate dihydrate; povidone; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; magnesium stearate - mobic tablets and capsules are indicated for the symptomatic treatment of osteoarthritis and rheumatoid arthritis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dipyridamole -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; mannitol; colloidal anhydrous silica; magnesium stearate - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.